114 related articles for article (PubMed ID: 38430628)
21. Characterization and modulation of drug transport kinetics in K562 c1.6 daunorubicin-resistant cell line.
Jiang XR; Macey MG; Collins PW; Newland AC
Br J Haematol; 1994 Mar; 86(3):547-54. PubMed ID: 8043436
[TBL] [Abstract][Full Text] [Related]
22. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
23. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
Danesh NM; Lavaee P; Ramezani M; Abnous K; Taghdisi SM
Int J Pharm; 2015 Jul; 489(1-2):311-7. PubMed ID: 25936625
[TBL] [Abstract][Full Text] [Related]
24. NGR-peptide-drug conjugates with dual targeting properties.
Enyedi KN; Tóth S; Szakács G; Mező G
PLoS One; 2017; 12(6):e0178632. PubMed ID: 28575020
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
[TBL] [Abstract][Full Text] [Related]
26. Amphiphilic drug-peptide-polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of conjugate aggregation on in vitro activity.
Pethő L; Kasza G; Lajkó E; Láng O; Kőhidai L; Iván B; Mező G
Soft Matter; 2020 Jun; 16(24):5759-5769. PubMed ID: 32530018
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH-Peptide Conjugates.
Szabó I; Biri-Kovács B; Vári B; Ranđelović I; Vári-Mező D; Juhász É; Halmos G; Bősze S; Tóvári J; Mező G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256168
[TBL] [Abstract][Full Text] [Related]
28. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
Tripodi AAP; Tóth S; Enyedi KN; Schlosser G; Szakács G; Mező G
Beilstein J Org Chem; 2018; 14():911-918. PubMed ID: 29765472
[TBL] [Abstract][Full Text] [Related]
29. Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling.
Perchellet EM; Wang Y; Weber RL; Lou K; Hua DH; Perchellet JP
Anticancer Drugs; 2004 Nov; 15(10):929-46. PubMed ID: 15514562
[TBL] [Abstract][Full Text] [Related]
30. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.
Szabó I; Manea M; Orbán E; Csámpai A; Bosze S; Szabó R; Tejeda M; Gaál D; Kapuvári B; Przybylski M; Hudecz F; Mezo G
Bioconjug Chem; 2009 Apr; 20(4):656-65. PubMed ID: 19296605
[TBL] [Abstract][Full Text] [Related]
31. Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
Schreier VN; Pethő L; Orbán E; Marquardt A; Petre BA; Mező G; Manea M
PLoS One; 2014; 9(4):e94041. PubMed ID: 24718594
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
[TBL] [Abstract][Full Text] [Related]
33. Effects of 3'-(4-morpholinyl)-3'-deaminodaunorubicin,3'- (4-methoxy-1-piperidinyl)-3'-deaminodaunorubicin and daunorubicin on nuclear and polysomal RNA synthesis in human colon carcinoma cells in vitro.
Johnston JB; Begleiter A; Glazer RI
Cancer Lett; 1986 Nov; 33(2):225-33. PubMed ID: 3791193
[TBL] [Abstract][Full Text] [Related]
34. Electroporation with Cisplatin against Metastatic Pancreatic Cancer:
Michel O; Kulbacka J; Saczko J; Mączyńska J; Błasiak P; Rossowska J; Rzechonek A
Biomed Res Int; 2018; 2018():7364539. PubMed ID: 29750170
[TBL] [Abstract][Full Text] [Related]
35. Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines.
Wang Y; Perchellet EM; Tamura M; Hua DH; Perchellet JP
Cancer Lett; 2002 Dec; 188(1-2):73-83. PubMed ID: 12406551
[TBL] [Abstract][Full Text] [Related]
36. 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
Perchellet EM; Magill MJ; Huang X; Dalke DM; Hua DH; Perchellet JP
Anticancer Drugs; 2000 Jun; 11(5):339-52. PubMed ID: 10912950
[TBL] [Abstract][Full Text] [Related]
37. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis.
Gervasoni JE; Hindenburg AA; Vezeridis MP; Schulze S; Wanebo HJ; Mehta S
Anticancer Res; 2004; 24(5A):2617-26. PubMed ID: 15517865
[TBL] [Abstract][Full Text] [Related]
38. [Application of Asn-Gly-Arg sequence based cyclic peptides for targeted tumor therapy].
Mező GM; Tripodi Angelo Pierluigi ATAP; Ranđelovič IR; Enyedi NKE; Biri-Kovács BB; Tóvári JT
Magy Onkol; 2021 Jun; 65(2):113-120. PubMed ID: 34081759
[TBL] [Abstract][Full Text] [Related]
39. Enhanced targeting of 3D pancreatic cancer spheroids by aptamer-conjugated polymeric micelles with deep tumor penetration.
Tian L; Pei R; Zhong L; Ji Y; Zhou D; Zhou S
Eur J Pharmacol; 2021 Mar; 894():173814. PubMed ID: 33352182
[TBL] [Abstract][Full Text] [Related]
40. Daunomycin-polypeptide conjugates with antitumor activity.
Szabó R; Bánóczi Z; Mezo G; Láng O; Kohidai L; Hudecz F
Biochim Biophys Acta; 2010 Dec; 1798(12):2209-16. PubMed ID: 20659420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
